Tags

Type your tag names separated by a space and hit enter

Aliskiren for geriatric lowering of systolic hypertension: a randomized controlled trial.
J Hum Hypertens. 2010 Sep; 24(9):600-8.JH

Abstract

Efficacy and safety of the direct renin inhibitor aliskiren was compared with ramipril for treatment of essential systolic hypertension in elderly patients. A 36-week, randomized, double-blind, parallel-group, active-controlled, optional-titration study was performed in 901 patients (aliskiren, n=457; ramipril, n=444) > or =65 years of age with systolic blood pressure (SBP) > or =140 mm Hg. Aliskiren 150-300 mg per day or ramipril 5-10 mg per day for was administered for 12 weeks with optional add-on therapy of hydrochlorothiazide (12.5-25 mg per day) at week 12 and amlodipine (5-10 mg per day) at week 22. The primary end point was non-inferiority of aliskiren vs ramipril monotherapy for change from baseline in mean sitting SBP (msSBP) at week 12. Decreases from baseline msSBP and mean sitting diastolic BP with aliskiren monotherapy (-14.0 and -5.1 mm Hg, respectively) were non-inferior (P<0.001 for both values) and superior to ramipril monotherapy (-11.6, -3.6 mm Hg; P=0.02, P<0.01, respectively). More patients achieved BP control with aliskiren (42%) than ramipril (33%; P<0.01). At week 36, fewer patients receiving aliskiren-based therapy required add-on treatment with hydrochlorothiazide or amlodipine (P=0.01 and 0.048, respectively). Tolerability was similar, but more patients receiving ramipril reported cough (P<0.001). In elderly patients with systolic hypertension, aliskiren proved to be more effective and better overall anti-hypertensive therapy compared to ramipril.

Authors+Show Affiliations

Cardiovascular Division, Medical School, University of Minnesota, Minneapolis, MN 55544, USA. dupre007@umn.eduNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

20033075

Citation

Duprez, D A., et al. "Aliskiren for Geriatric Lowering of Systolic Hypertension: a Randomized Controlled Trial." Journal of Human Hypertension, vol. 24, no. 9, 2010, pp. 600-8.
Duprez DA, Munger MA, Botha J, et al. Aliskiren for geriatric lowering of systolic hypertension: a randomized controlled trial. J Hum Hypertens. 2010;24(9):600-8.
Duprez, D. A., Munger, M. A., Botha, J., Keefe, D. L., & Charney, A. N. (2010). Aliskiren for geriatric lowering of systolic hypertension: a randomized controlled trial. Journal of Human Hypertension, 24(9), 600-8. https://doi.org/10.1038/jhh.2009.107
Duprez DA, et al. Aliskiren for Geriatric Lowering of Systolic Hypertension: a Randomized Controlled Trial. J Hum Hypertens. 2010;24(9):600-8. PubMed PMID: 20033075.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Aliskiren for geriatric lowering of systolic hypertension: a randomized controlled trial. AU - Duprez,D A, AU - Munger,M A, AU - Botha,J, AU - Keefe,D L, AU - Charney,A N, Y1 - 2009/12/24/ PY - 2009/12/25/entrez PY - 2009/12/25/pubmed PY - 2010/12/14/medline SP - 600 EP - 8 JF - Journal of human hypertension JO - J Hum Hypertens VL - 24 IS - 9 N2 - Efficacy and safety of the direct renin inhibitor aliskiren was compared with ramipril for treatment of essential systolic hypertension in elderly patients. A 36-week, randomized, double-blind, parallel-group, active-controlled, optional-titration study was performed in 901 patients (aliskiren, n=457; ramipril, n=444) > or =65 years of age with systolic blood pressure (SBP) > or =140 mm Hg. Aliskiren 150-300 mg per day or ramipril 5-10 mg per day for was administered for 12 weeks with optional add-on therapy of hydrochlorothiazide (12.5-25 mg per day) at week 12 and amlodipine (5-10 mg per day) at week 22. The primary end point was non-inferiority of aliskiren vs ramipril monotherapy for change from baseline in mean sitting SBP (msSBP) at week 12. Decreases from baseline msSBP and mean sitting diastolic BP with aliskiren monotherapy (-14.0 and -5.1 mm Hg, respectively) were non-inferior (P<0.001 for both values) and superior to ramipril monotherapy (-11.6, -3.6 mm Hg; P=0.02, P<0.01, respectively). More patients achieved BP control with aliskiren (42%) than ramipril (33%; P<0.01). At week 36, fewer patients receiving aliskiren-based therapy required add-on treatment with hydrochlorothiazide or amlodipine (P=0.01 and 0.048, respectively). Tolerability was similar, but more patients receiving ramipril reported cough (P<0.001). In elderly patients with systolic hypertension, aliskiren proved to be more effective and better overall anti-hypertensive therapy compared to ramipril. SN - 1476-5527 UR - https://www.unboundmedicine.com/medline/citation/20033075/Aliskiren_for_geriatric_lowering_of_systolic_hypertension:_a_randomized_controlled_trial_ L2 - https://doi.org/10.1038/jhh.2009.107 DB - PRIME DP - Unbound Medicine ER -